AOX1 and metabolic dysfunction-associated steatotic liver disease: Conversely, HYD effectively decreased body weight and liver weight (Figures 3(f) and S3E), mitigated hepatic lipid deposition and lipid metabolic disorder (Figures 3(g–i)), and improved the condition of epididymal adipose tissue (Figure S3H-I) in HFD mice, suggesting that inhibition of hepatic AOX1 might be a potential therapeutic strategy for NAFLD.